Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2025
Reporting Period: Event-based report for July 14, 2025
The filing reports a significant corporate event under Item 8.01 (Other Events). Corcept Therapeutics announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary selective cortisol modulator, relacorilant. The proposed indication is for the treatment of patients with platinum-resistant ovarian cancer.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the advancement of the company's clinical pipeline. Specifically, the company has progressed relacorilant from clinical development to the regulatory review stage for a new oncology indication (platinum-resistant ovarian cancer). No financial or operational changes compared to a prior period are detailed in this document.
Guidance, Outlook, and Risks
Outlook: The submission of the NDA represents a positive development in the company's drug development pipeline, potentially expanding its market reach into oncology.
Risks and Contingencies: While not explicitly detailed in the 8-K text, the standard risk associated with an NDA submission is the uncertainty of FDA approval. The outcome of the regulatory review remains a key contingency for the commercial viability of relacorilant in this indication.
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) which likely contains further management commentary, but the 8-K text itself is limited to the announcement of the submission.
Investor Verification Checklist
- Verify the specific clinical data supporting the NDA submission for relacorilant in platinum-resistant ovarian cancer by reviewing the attached press release (Exhibit 99.1).
- Monitor FDA communications for the acceptance of the NDA for review and any subsequent PDUFA dates.
- Assess the potential market size and competitive landscape for treatments in platinum-resistant ovarian cancer.
- Review upcoming quarterly earnings reports for any impact on R&D expenses or cash burn rate related to this regulatory filing.